Microsatellite instability (MSI), p53 expression and intratumoral microvessel density (IMD) in gastric carcinoma (GC): Correlations with clinicopathological parameters and survival rates

2005 ◽  
Vol 23 (16_suppl) ◽  
pp. 4158-4158
Author(s):  
S. Meditskou ◽  
P. Stravoravdi ◽  
I. Boukovinas ◽  
I. Stergiou ◽  
G. Geromichalos ◽  
...  
2017 ◽  
Vol 6 (3) ◽  
pp. 2370-2375 ◽  
Author(s):  
Tushar Hiralal Sankalecha ◽  
◽  
Sudhir Jagdish Gupta ◽  
Nitin Rangrao Gaikwad ◽  
Suresh Narayanrao Ughade

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 10022-10022
Author(s):  
F. A. Sinicrope ◽  
M. Garrity ◽  
R. L. Rego ◽  
A. J. French ◽  
N. R. Foster ◽  
...  

10022 Background: Patients with colon cancers displaying high frequency microsatellite instability (MSI-H) are reported to have a favorable prognosis compared to microsatellite stable (MSS) tumors. However, prognostic factors underlying this observation are poorly understood. We studied apoptotic and proliferative indices and their relationship to MSI status, clinicopathological features, and patient survival rates. Methods: Archival Dukes’ stage B2 (n=83) and C (n=246) primary colon adenocarcinomas from patients enrolled in five 5-fluorouracil-based adjuvant therapy trials were analyzed for MSI using a PCR-based assay (MSI-H: ≥30% of loci with instability), and expression of hMLH1, hMSH2 and p53 proteins by immunostaining. Apoptosis was analyzed by the TUNEL assay and the proliferative index (PI: S phase + G2M) and DNA ploidy by flow cytometry. Correlations between markers and associations with overall survival (OS) censored at 8 yrs were sought. Results: MSI-H (n=58.18%) tumors were more likely proximal, diploid, high grade, p53 negative (vs. MSS/MSI-L; all p<0.0001), and from women (p=0.002). Of 58 MSH-H cases tested, 54 showed loss of hMLH1 (n=50) or hMSH2 (n=4) proteins. Median proliferative index (PI) [12.6 vs. 17.4; p=0.0002] was reduced in MSI-H versus MSS/MSI-L tumors. Lower PI was associated with diploidy (p<0.0001) and negative p53 expression (p=0.003). Apoptotic indices (AIs) were increased in MSI-H cancers (vs. MSS/MSI-L, p=0.082), as was the AI/PI ratio (p=0.0065). Interestingly, AI (p=0.02) and AI/PI (p<0.0001) were significantly increased in diploid versus nondiploid tumors, and after removal of MSI-H cases, relationships held for PI and AI/PI with ploidy. Better OS was related to MSI-H (p=0.032), loss of hMLH1 or hMSH2 (p=0.024), diploidy (p=0.0015), and lower PI (p=0.078), but not AI, AI/PI, nor p53 (adjusting for stage, grade, treatment and stratifying by study). Conclusions: MSI-H tumors are characterized by reduced proliferative indices and a higher ratio of apoptosis to proliferation, reflecting slower tumor growth rates compared to MSS/MSI-L tumors. These features may contribute to their better survival. Lower PI and increased AI/PI are also features of diploid MSS cancers. [Table: see text]


2017 ◽  
Vol 10 ◽  
pp. 117906601773156 ◽  
Author(s):  
Mohammad Althubiti

Spleen tyrosine kinase (SYK) is a cytoplasmic enzyme that promotes survival and proliferation of B cells. SYK inhibition has shown promising results in the treatment of arthritis and chronic lymphocytic leukemia (CLL). However, in other context, it has been shown that SYK overexpression in epithelial cancer cells induced senescence in p53-dependent mechanism, which underscored its antineoplastic activity in vitro. Here, we show that SYK was induced in response of DNA damage in parallel with p53 levels. In addition, using chemical inhibitors of SYK reduced p53 levels in HCT116 and HT1080 cell lines, which underlines the role of SYK inhibition on p53 activity. Furthermore, SYK inhibition modulated the cell growth, which resulted in a decreasing in cell death. Interestingly, SYK expression showed a positive prognosis in patients with solid tumors in correlations with their survival rates, as expected negative correlation was seen between SYK expression and survival rate of patients with CLL. In conclusion, these findings demonstrate that SYK inhibition modulates p53 expression and activity in HCT116 and HT1080 cells. Reconsidering using of SYK inhibitors in clinical setting in the future should be evaluated carefully in accordance with these findings to prevent the formation of secondary malignancies.


1997 ◽  
Vol 182 (2) ◽  
pp. 167-173 ◽  
Author(s):  
GIOVANNI BUONSANTI ◽  
DANIELE CALISTRI ◽  
LAURA PADOVAN ◽  
OMBRETTA LUINETTI ◽  
ROBERTO FIOCCA ◽  
...  

2017 ◽  
Vol 14 (2) ◽  
pp. 2422-2426
Author(s):  
Xiao-Yan Zhu ◽  
Ji-Yao Yang ◽  
Ying He ◽  
Guo-Hong Liu ◽  
Yun Sun ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document